{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.6","upperLimit":"25.8","value":"20.3"},{"groupId":"OG001","lowerLimit":"6.4","upperLimit":"14.1","value":"9.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;","dispersionType":"95% Confidence Interval","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The ITT analysis set included all randomized participants","reportingStatus":"POSTED","timeFrame":"Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)","title":"Objective Response Rate (ORR) in the ITT Analysis Set","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}